Importer of Controlled Substances; Notice of Application; Johnson Matthey, Inc., 70824-70825 [2012-28667]

Download as PDF wreier-aviles on DSK5TPTVN1PROD with 70824 Federal Register / Vol. 77, No. 228 / Tuesday, November 27, 2012 / Notices including consultants and other persons retained by the United States, shall, upon written request of an authorized representative of the Assistant Attorney General in charge of the Antitrust Division, and on reasonable notice to defendants, be permitted: (1) access during defendants’ office hours to inspect and copy, or at the option of the United States, to require defendants to provide hard copies or electronic copies of, all books, ledgers, accounts, records, data and documents in the possession, custody or control of defendants, relating to any matters contained in this Final Judgment; and (2) to interview, either informally or on the record, defendants’ officers, employees, or agents, who may have their individual counsel present, regarding such matters. The interviews shall be subject to the reasonable convenience of the interviewee and without restraint or interference by defendants. B. Upon the written request of an authorized representative the Assistant Attorney General in charge of the Antitrust Division, defendants shall submit such written reports or responses to written interrogatories, under oath if requested, relating to any of the matters contained in this Final Judgment as may be requested. C. No information or documents obtained by the means provided in this section shall be divulged by the United States to any person other than an authorized representative of the executive branch of the United States, except in the course of legal proceedings to which the United States is a party (including grand jury proceedings), or for the purpose of securing compliance with this Final Judgment, or as otherwise required by law. D. If at the time information or documents are furnished by defendants to the United States, defendants represent and identify in writing the material in any such information or documents to which a claim of protection may be asserted under Rule 26(c)(1)(G) of the Federal Rules of Civil Procedure, and defendants mark each pertinent page of such material, ‘‘Subject to claim of protection under Rule 26(c)(1)(G) of the Federal Rules of Civil Procedure,’’ then the United States shall give defendants ten (10) calendar days notice prior to divulging such material in any legal proceeding (other than a grand jury proceeding). XII. No Reacquisition During the term of this Final Judgment, defendants may not reacquire any part of the Divestiture Assets, nor may any defendant participate in any VerDate Mar<15>2010 15:05 Nov 26, 2012 Jkt 229001 other transaction that would result in a combination, merger, or other joining together of any parts of the Divestiture Assets with assets of the divesting company. XIII. Retention of Jurisdiction This Court retains jurisdiction to enable any party to this Final Judgment to apply to this Court at any time for further orders and directions as may be necessary or appropriate to carry out or construe this Final Judgment, to modify any of its provisions, to enforce compliance, and to punish violations of its provisions. Drug Thebaine (9333) ........................... Opium, raw (9600) ....................... Noroxymorphone (9668) .............. Poppy Straw Concentrate (9670) Schedule II II II II The company plans to import the listed controlled substances as raw materials, to be used in the manufacture of bulk controlled substances, for distribution to its customers. No comments, objections, or requests for any hearings will be accepted on any application for registration or reregistration to import crude opium, XIV. Expiration of Final Judgment poppy straw, concentrate of poppy Unless this Court grants an extension, straw, and coca leaves. Comments and this Final Judgment shall expire ten (10) requests for hearings on applications to import narcotic raw material are not years from the date of its entry. appropriate, in accordance with 72 FR XV. Public Interest Determination 3417 (2007). Entry of this Final Judgment is in the In reference to the non-narcotic raw public interest. The parties have material, the company plans to import complied with the requirements of the gram amounts to be used as reference Antitrust Procedures and Penalties Act, standards for sale to its customers. Any 15 U.S.C. § 16, including making copies bulk manufacturer who is presently, or available to the public of this Final is applying to be, registered with DEA Judgment, the Competitive Impact to manufacture such basic classes of Statement, and any comments thereon, controlled substances listed in schedule and the United States’s responses to I or II, which fall under the authority of comments. Based upon the record section 1002(a)(2)(B) of the Act (21 before the Court, which includes the U.S.C. 952(a)(2)(B)) may, in the Competitive Impact Statement and any circumstances set forth in 21 U.S.C. comments and responses to comments 958(i), file comments or objections to filed with the Court, entry of this Final the issuance of the proposed registration Judgment is in the public interest. and may, at the same time, file a written Date: llllllllllllllll request for a hearing on such application pursuant to 21 CFR 1301.43 Court approval subject to procedures of and in such form as prescribed by 21 Antitrust Procedures and Penalties Act, CFR 1316.47. 15 U.S.C. § 16 llllllllllllllllll l Any such written comments or United States District Judge objections should be addressed, in [FR Doc. 2012–28730 Filed 11–26–12; 8:45 am] quintuplicate, to the Drug Enforcement BILLING CODE 4410–11–P Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, DEPARTMENT OF JUSTICE Springfield, Virginia 22152; and must be filed no later than December 27, 2012. Drug Enforcement Administration This procedure is to be conducted Importer of Controlled Substances; simultaneously with, and independent Notice of Application; Johnson of, the procedures described in 21 CFR Matthey, Inc. 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Pursuant to Title 21 Code of Federal Federal Register on September 23, 1975, Regulations 1301.34(a), this is notice 40 FR 43745, all applicants for that on September 10, 2012, Johnson Matthey, Inc., Pharmaceutical Materials, registration to import a basic class of any controlled substance in schedules I 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by or II are, and will continue to be, required to demonstrate to the Deputy renewal to the Drug Enforcement Administration (DEA) for registration as Assistant Administrator, Office of Diversion Control, Drug Enforcement an importer of the following basic Administration, that the requirements classes of controlled substances: for such registration pursuant to 21 Drug Schedule U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Coca Leaves (9040) ..................... II PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 E:\FR\FM\27NON1.SGM 27NON1 Federal Register / Vol. 77, No. 228 / Tuesday, November 27, 2012 / Notices Dated: November 19, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Dated: November 19, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–28667 Filed 11–26–12; 8:45 am] [FR Doc. 2012–28664 Filed 11–26–12; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Norac Manufacturer of Controlled Substances; Notice of Application; Siegfried (USA), LLC Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 5, 2012, Siegfried (USA) LLC, 33 Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule wreier-aviles on DSK5TPTVN1PROD with Gamma Hydroxybutyric Acid (2010). Dihydromorphine (9145) ............... Hydromorphinol (9301) ................. Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Oripavine (9330) ........................... Oxymorphone (9652) ................... I I I II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than January 28, 2013. VerDate Mar<15>2010 15:05 Nov 26, 2012 Jkt 229001 Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on October 31, 2012, Norac, DBA: Norac Pharma, 405 S. Motor Avenue, Azusa, California 91702–3232, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule Gamma Hydroxybutyric Acid (2010). Tetrahydrocannabinols (7370) ..... Methamphetamine (1105) ............ Pentobarbital (2270) ..................... Nabilone (7379) ............................ I I II II II With regard to gamma hydroxybutyric acid (2010), tetrahydrocannabinols (7370), and methamphetamine (1105) only, the company manufactures these controlled substances in bulk solely for domestic distribution within the United States to customers engaged in dosageform manufacturing. With regard to Nabilone (7379), the company presently manufactures a small amount of this controlled substance in bulk solely to conduct manufacturing process development internally within the company. It is the company’s intention that, when the manufacturing process is refined to the point that its Nabilone bulk product is available for commercial use, the company will export the controlled substance in bulk solely to customers engaged in dosage-form manufacturing outside the United States. The company is aware of the requirement to obtain a DEA registration as an exporter to conduct this activity. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 70825 quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than January 28, 2013. Dated: November 19, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–28662 Filed 11–26–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Office of the Secretary Agency Information Collection Activities; Submission for OMB Review; Comment Request; DOL Generic Solution for Customer Satisfaction Surveys and Conference Evaluations ACTION: Notice. The Department of Labor (DOL) is submitting the information collection request (ICR) titled, ‘‘DOL Generic Solution for Customer Satisfaction Surveys and Conference Evaluations,’’ to the Office of Management and Budget (OMB) for review and approval for continued use in accordance with the Paperwork Reduction Act (PRA) of 1995 (44 U.S.C. 3501 et seq.). DATES: Submit comments on or before December 27, 2012. ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained from the RegInfo.gov Web site, https://www.reginfo.gov/ public/do/PRAMain, on the day following publication of this notice or by contacting Michel Smyth by telephone at 202–693–4129 (this is not a toll-free number) or sending an email to DOL_PRA_PUBLIC@dol.gov. Submit comments about this request to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for DOL-Departmental Management, Office of Management and Budget, Room 10235, 725 17th Street, NW., Washington, DC 20503, Fax: 202– 395–6881 (this is not a toll-free number), email: OIRA_submission@omb.eop.gov. SUMMARY: FOR FURTHER INFORMATION CONTACT: Michel Smyth by telephone at 202–693– 4129 (this is not a toll-free number) or by email at DOL_PRA_PUBLIC@dol.gov. E:\FR\FM\27NON1.SGM 27NON1

Agencies

[Federal Register Volume 77, Number 228 (Tuesday, November 27, 2012)]
[Notices]
[Pages 70824-70825]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-28667]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application; Johnson 
Matthey, Inc.

    Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this 
is notice that on September 10, 2012, Johnson Matthey, Inc., 
Pharmaceutical Materials, 2003 Nolte Drive, West Deptford, New Jersey 
08066-1742, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as an importer of the following 
basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Coca Leaves (9040).........................  II
Thebaine (9333)............................  II
Opium, raw (9600)..........................  II
Noroxymorphone (9668)......................  II
Poppy Straw Concentrate (9670).............  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances as raw 
materials, to be used in the manufacture of bulk controlled substances, 
for distribution to its customers.
    No comments, objections, or requests for any hearings will be 
accepted on any application for registration or re-registration to 
import crude opium, poppy straw, concentrate of poppy straw, and coca 
leaves. Comments and requests for hearings on applications to import 
narcotic raw material are not appropriate, in accordance with 72 FR 
3417 (2007).
    In reference to the non-narcotic raw material, the company plans to 
import gram amounts to be used as reference standards for sale to its 
customers. Any bulk manufacturer who is presently, or is applying to 
be, registered with DEA to manufacture such basic classes of controlled 
substances listed in schedule I or II, which fall under the authority 
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in 
the circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than December 27, 2012.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745, all applicants for 
registration to import a basic class of any controlled substance in 
schedules I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 
1301.34(b), (c), (d), (e), and (f) are satisfied.


[[Page 70825]]


     Dated: November 19, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-28667 Filed 11-26-12; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.